# Peptidase Inhibition and Analysis
**Type:** Topics
**Canonical URL:** https://scholariq.org/topics/peptidase-inhibition-and-analysis/
## Facts
| Field | Value |
| --- | --- |
| Description | This cluster of papers explores the role of fibroblast activation in cancer progression, focusing on the expression of fibroblast activation protein, immunosuppression in the tumor microenvironment, N-terminal acetylation of proteins, protease inhibitors for cancer therapy, angiogenesis, and PET imaging to target stromal cells in the tumor microenvironment. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t12505 |
| Works | 278 |
## Topic papers all
Showing 15 of 278.
- [Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-pd-l1-positive-non-small-cell-lung-cancer/)
- [Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer/)
- [Erlotinib in Previously Treated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/erlotinib-in-previously-treated-non-small-cell-lung-cancer/)
- [Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell/)
- [Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-for-squamous-non-small-cell-lung-cancer/)
- [First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung/)
- [International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma](https://scholariq.org/papers/international-myeloma-working-group-consensus-criteria-for-response-and-minimal/)
- [Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-for-patients-with-previously-treated-non-small/)
- [Trastuzumab — Mechanism of Action and Use in Clinical Practice](https://scholariq.org/papers/trastuzumab-mechanism-of-action-and-use-in-clinical-practice/)
- [Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints](https://scholariq.org/papers/adaptive-resistance-to-therapeutic-pd-1-blockade-is-associated-with-upregulation/)
- [Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1](https://scholariq.org/papers/endoglin-a-tgf-binding-protein-of-endothelial-cells-is-the-gene-for-hereditary/)
- [Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial](https://scholariq.org/papers/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for/)
- [Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension: A Double-blind, Randomized, Placebo-controlled Trial](https://scholariq.org/papers/continuous-subcutaneous-infusion-of-treprostinil-a-prostacyclin-analogue-in/)
- [Catalytic in vivo protein knockdown by small-molecule PROTACs](https://scholariq.org/papers/catalytic-in-vivo-protein-knockdown-by-small-molecule-protacs/)
- [Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer](https://scholariq.org/papers/trastuzumab-deruxtecan-in-i-her2-i-mutant-non-small-cell-lung-cancer/)
## Topic primary papers
Showing 15 of 47.
- [(2R)-4-Oxo-4-\[3-(Trifluoromethyl)-5,6-dihydro\[1,2,4\]triazolo\[4,3-a\]pyrazin- 7(8H)-yl\]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes](https://scholariq.org/papers/2-i-r-i-4-oxo-4-3-trifluoromethyl-5-6-dihydro-1-2-4-triazolo-4-3-i-a-i-pyrazin-7/)
- [Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26](https://scholariq.org/papers/molecular-basis-of-binding-between-novel-human-coronavirus-mers-cov-and-its/)
- [Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy](https://scholariq.org/papers/cardiac-hypertrophy-is-inhibited-by-antagonism-of-adam12-processing-of-hb-egf/)
- [Comparison of \[68Ga\]Ga-DOTA-FAPI-04 and \[18F\] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer](https://scholariq.org/papers/comparison-of-68ga-ga-dota-fapi-04-and-18f-fdg-pet-ct-for-the-diagnosis-of/)
- [The moonlighting enzyme CD13: old and new functions to target](https://scholariq.org/papers/the-moonlighting-enzyme-cd13-old-and-new-functions-to-target/)
- [Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen](https://scholariq.org/papers/linagliptin-mediated-dpp-4-inhibition-ameliorates-kidney-fibrosis-in/)
- [Structural Basis of Proline-Specific Exopeptidase Activity as Observed in Human Dipeptidyl Peptidase-IV](https://scholariq.org/papers/structural-basis-of-proline-specific-exopeptidase-activity-as-observed-in-human/)
- [Fibroblast Activation Protein Overexpression and Clinical Implications in Solid Tumors: A Meta-Analysis](https://scholariq.org/papers/fibroblast-activation-protein-overexpression-and-clinical-implications-in-solid/)
- [NAAG peptidase inhibitors and their potential for diagnosis and therapy](https://scholariq.org/papers/naag-peptidase-inhibitors-and-their-potential-for-diagnosis-and-therapy/)
- [4-Aryl-1,2,3-triazole: A Novel Template for a Reversible Methionine Aminopeptidase 2 Inhibitor, Optimized To Inhibit Angiogenesis in Vivo](https://scholariq.org/papers/4-aryl-1-2-3-triazole-a-novel-template-for-a-reversible-methionine/)
- [Targeting Carcinoma-Associated Fibroblasts Within the Tumor Stroma With a Fibroblast Activation Protein-Activated Prodrug](https://scholariq.org/papers/targeting-carcinoma-associated-fibroblasts-within-the-tumor-stroma-with-a/)
- [Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin β1/Src/Akt-Driven Bypass Signaling](https://scholariq.org/papers/erlotinib-resistance-in-lung-cancer-cells-mediated-by-integrin-1-src-akt-driven/)
- [Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice](https://scholariq.org/papers/long-term-inhibition-of-dipeptidyl-peptidase-4-in-alzheimer-s-prone-mice/)
- [Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study](https://scholariq.org/papers/correlation-of-sup-68-sup-ga-fapi-46-pet-biodistribution-with-fap-expression-by/)
- [CD13/APN regulates endothelial invasion and filopodia formation](https://scholariq.org/papers/cd13-apn-regulates-endothelial-invasion-and-filopodia-formation/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.